Fundz
Real-time · AI · Cross-signal

Duality Biologics just moved. Here's exactly what to do next.

Who to reach, what to say, and why now — on Duality Biologics, plus every contract, funding round, and exec hire that follows. Verified, ICP-ranked contacts on demand (email + mobile).

Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.

Choose your planRequest a demo
Watch the 2-minute tour · with sound

Expansion of Collaboration between Duality Biologics and Adcendo ApS for ADC Pipeline Enhancement

Nov 26, 2024over 1 year ago

Contract Type

partnership

BiotechnologyTherapeuticsBiopharma

Description

Duality Biologics announced the expansion of its ongoing collaboration with Adcendo ApS, focusing on the development of first-in-class antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical need. Adcendo exercised its option to utilize Duality’s technology platform to be used in additional assets, further strengthening its ADC pipeline.

Company Information

Company

Duality Biologics

About

Duality Biologics is a clinical-stage biotech company focusing on the discovery and development of next generation antibody-drug conjugate therapeutics.

Predictive Intelligence
Strategic

ML-powered predictions for Duality Biologics's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months